ABBV-295 registry update: Phase 1 obesity study stays active not recruiting
AbbVie’s phase 1 ABBV-295 study in healthy adult Japanese participants with overweight or obesity is active not recruiting, with primary completion estimated for 2026-12 and no results posted yet.
AbbVie’s ABBV-295 trial is still listed as ACTIVE_NOT_RECRUITING, so the main takeaway for readers is status rather than results. The phase 1 study is focused on healthy adult Japanese participants with overweight or obesity, and its primary completion is estimated for 2026-12.
That means the trial is still in a safety-and-measurement stage. The study is designed to look at adverse events, tolerability, and pharmacokinetics, which is the way a drug is absorbed, distributed, and cleared by the body.
"This record describes a study and its registry status; study outcomes require posted results."
What the study is testing
The study title names subcutaneous injections of ABBV-295, with placebo arms included for both Part 1 and Part 2. The trial is randomized, which means participants are assigned by chance to one of the study arms rather than chosen by preference.
Its primary outcome is the Number of Participants with Adverse Events (AEs) over up to approximately 145 days. The registry definition notes that an adverse event is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product, and that the investigator assesses whether it is related to the study treatment.
"An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment."
Why this fits the wider obesity and metabolic picture
Within the Obesity & Metabolic special event, this ABBV-295 update sits alongside other clinical trial listings that range from early-stage studies to recruiting phase 3 programs. The shared theme is straightforward: researchers are still testing different approaches to obesity, overweight, related comorbidity, and metabolism.
That broader mix matters because it shows how many questions remain open even before results arrive. In this case, the useful news is simply that the study is active, not recruiting, and therefore not yet at the point where posted outcomes can change the picture.
"Study outcomes require posted results."
What readers should watch next
For now, the most important marker is the estimated primary completion date of 2026-12. Until results are posted, the registry can only tell readers what the study plans to measure, not what ABBV-295 does or does not do.
When results eventually appear, they should help answer whether the trial found anything notable on adverse events, tolerability, and pharmacokinetics in this participant group. Until then, the registry status is the clearest signal available.
"Primary completion date": "2026-12"